Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2019-11-06 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please find attached press release dated 06th November, 2019
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 6, 2019, announcing Cipla Limited's unaudited consolidated financial results for the quarter ended September 30, 2019 (Q2 FY20). It contains detailed financial data including revenue, EBITDA, PAT, business-wise sales performance, and balance sheet items. The document also mentions an earnings conference call to discuss these results. The presence of comprehensive quarterly financial statements and analysis indicates this is a quarterly financial report rather than a brief earnings release or just an announcement. The document length (11,839 characters) supports it being a full report rather than a short announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2019-11-06 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 6, 2019, announcing Cipla Limited's unaudited consolidated financial results for the quarter ended September 30, 2019 (Q2 FY20). It contains detailed financial highlights including revenue, EBITDA, PAT, business-wise sales performance, and balance sheet items. The document also mentions an earnings conference call scheduled to discuss these results. The presence of actual financial data and analysis for a quarterly period indicates this is a quarterly financial report. It is not merely an announcement of a report or a certification, but a substantive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2019-11-06 English
Please find enclosed letter dated 6th November, 2019.
Regulatory Filings
2019-11-06 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 90% confidence The document contains details about stock options granted under a scheme compliant with SEBI regulations, including number of options, exercise price, vesting period, and exercise period. This is indicative of a disclosure related to share-based compensation or stock option plans. It does not contain financial statements, audit information, or meeting results. It is not a full report but a specific announcement about share options granted. This fits best under the category of Share Issue/Capital Change (SHA), as it relates to issuance of options which can convert into shares.
2019-11-05 English
Please find attached letter dated 5th November, 2019
Share Issue/Capital Change Classification · 95% confidence The document text describes details about stock options granted, including number of options, exercise price, vesting period, and exercise period. It references SEBI (Securities and Exchange Board of India) regulations related to stock option schemes. This type of information typically relates to share-based compensation or share option plans. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory filing or announcement of a report. The content fits best with a report on share-based compensation or share option scheme details, which is commonly classified under Share Issue/Capital Change (SHA) because it involves issuance of options and potential future shares. The document length is short and focused on option grant details, not a full report or announcement of voting results or management changes. Therefore, the best classification is SHA with high confidence.
2019-11-05 English
Please find enclosed Certificate from a practicing company secretary in compliance with Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text content. The true document length is only 453 characters, which is very short and contains no financial data, report content, or announcements. It does not contain any report, announcement, or regulatory filing information. Given the lack of content and the presence of only images, this document cannot be classified as a report or announcement type. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2019-10-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.